🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Stocks - Papa John’s, Clorox Soar in Premarket, Bristol-Myers, GE, GM Gain

Published 2019-02-04, 08:20 a/m
© Reuters.
GM
-
GS
-
CELG
-
CLX
-
DUK
-
BMY
-
GE
-
PZZA
-
EOLS
-
SPOT
-

Investing.com - Stocks in focus in premarket trade Monday:

• Papa John's (NASDAQ:PZZA) stock soared 6.02% by 8:14 AM ET (13:14 GMT) as the company confirmed that activist hedge fund Starboard Value was making a $200 million investment in the company.

• Bristol-Myers Squibb (NYSE:BMY) stock jumped 1.92% after Bloomberg reported that Starboard has also taken a stake in the drug company. Celgene (NASDAQ:CELG), which Bristol-Myers is aiming to buy for over $74 billion, is down 1.58% amid fears Starboard will try to revise the deal terms in Bristol-Myers' favor.

• Clorox (NYSE:CLX) stock surged 5.23% after the company reported better-than-expected profit for its fiscal second quarter.

General Electric (NYSE:GE) stock gained 0.59% after the company won a $517 million contract to build engines for the next generation of U.S. army helicopters.

• General Motors (NYSE:GM) stock rose 0.49% amid expectations that the company will begin another round of job cuts Monday, according to Detroit Free Press. Separately, GM said it was negotiating terms to invest about $2.7 billion in Brazil from 2020 to 2024.

• Goldman Sachs (NYSE:GS) stock dropped 0.27% after a weekend report in the Wall Street Journal that the company is considering withholding bonus payments from former CEO Lloyd Blankfein and others in relation to the scandal around its relationship with Malaysian wealth fund 1MDB.

Spotify Technology (NYSE:SPOT) stock advanced 0.77% as Recode reported it's in advanced talks to acquire Gimlet Media for more than $200 million.

Duke Energy (NYSE:DUK) stock rose 0.22% despite the fact that the company faces a record $10 million fine from federal authorities for failure to prevent physical and cyber attacks on national electricity systems, according to sources cited late Friday by The Wall Street Journal.

• Evolus (NASDAQ:EOLS) stock skyrocketed 22.48% after the U.S. Food & Drug Administration approved its treatment for frown lines. Prices are expected to be 20% to 25% lower than for rival Botox.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.